Increasing COVID-19, Influenza, and Pneumonia Vaccine Uptake

Improving Vaccine Acceptance and Uptake Among Underresourced African American and Latinx Older Adults: A Multidisciplinary and Culturally Based Training Program for Minority Churches

Sponsors

Lead Sponsor: Charles Drew University of Medicine and Science

Source Charles Drew University of Medicine and Science
Brief Summary

This proposed study seeks to community knowledge and understand the experience of underserved communities in the exploration of reducing health disparities and increasing vaccine uptake and acceptability COVID-19, influenza, and pneumonia for AA and Latinx populations. Unique in its design, it has the following characteristics: 1) multifaceted, 2) culturally tailored, 3) community-based, and 4) mixed methods in which the outcomes of interest will be measured before and after the intervention with 18-month interval. Furthermore, we seek to enhance our partnerships and collaborations with churches in South Los Angeles by supporting efforts to encourage COVID-19, influenza, and pneumonia vaccination uptake among underserved minorities in one of the most challenged and hard-to-reach population areas in the nation.

Detailed Description

This study seeks to augment community knowledge and increase vaccine uptake among under-resourced African American and Latinx communities in South LA via leveraging trusted church leaders, educators and influencers to delivering COVID-19, influenza, and pneumonia education on vaccination. Unique in its design, this study has the following characteristics, beneficial to the acceptability and success of the proposal, it is: 1) multifaceted, 2) culturally tailored, and 3) community-based, in which the outcomes of interest will be compared longitudinally between arms 1-3, including measurement before and after the intervention with 9- and 18-month interval.

Overall Status Not yet recruiting
Start Date October 1, 2021
Completion Date December 31, 2026
Primary Completion Date October 31, 2026
Phase N/A
Study Type Interventional
Primary Outcome
Measure Time Frame
Prevalence of vaccination uptake for COVID-19, influenza, and pneumonia using Vaccination History Self Report Intervention: 12 months; Follow-up Point: 9 & 18 months post-intervention
Secondary Outcome
Measure Time Frame
Percentage of Participants Achieving Adherence to COVID-19, influenza, and pneumonia vaccination schedules Risk Using the NIH Toolbox Surveys on COVID-19 Intervention: 12 months; Follow-up Point: 9 & 18 months post-intervention
Percentage of Participants Achieving Decreased Vaccine Hesitancy Levels of COVID-19, influenza, and pneumonia Using the NIH Toolbox Surveys on COVID-19, influenza, and pneumonia Intervention: 12 months; Follow-up Point: 9 & 18 months post-intervention
Percentage of Participants Achieving Decreased Levels of COVID-19, influenza, and pneumonia Mistrust and Barriers Using the NIH Toolbox Surveys on COVID-19, influenza, and pneumonia Intervention: 12 months; Follow-up Point: 9 & 18 months post-intervention
Enrollment 570
Condition
Intervention

Intervention Type: Behavioral

Intervention Name: Full VEPMP Intervention

Description: Delivery of intrapersonal/interpersonal (i.e., motivational interviewing, vaccine educators, personal testimony, etc.), AND organizational (i.e., church-based sponsored events, seminars, web/online activities, bulletin inserts, etc.)

Arm Group Label: Arm 1

Intervention Type: Behavioral

Intervention Name: Partial VEPMP Intervention

Description: Delivery of iAND organizational (i.e., church-based sponsored events, seminars, web/online activities, bulletin inserts, etc.)

Arm Group Label: Arm 2

Intervention Type: Behavioral

Intervention Name: Delayed VEPMP Intervention

Description: Delayed implementation of delivery of intrapersonal/interpersonal AND organizational after 1 year of study start

Arm Group Label: Arm 3

Eligibility

Criteria:

Inclusion Criteria: - Parishioner at a church receiving the VEPMP intervention - Identify as African American or Latinx, - at least 65 years and older - Have Not received a vaccine for COVID-19, influenza, or pneumonia within the previous 24 months - Agrees to study terms, which include follow-up interviews 9 and 18 months after study enrollment Exclusion Criteria: - Does not attend or identify as a Parishioner at a church receiving the VEPMP intervention - Does not identify as African American or Latinx - Under the age of 65 years - Received all vaccine doses for COVID-19, influenza, or pneumonia within the previous 24 months

Gender: All

Minimum Age: 65 Years

Maximum Age: N/A

Healthy Volunteers: Accepts Healthy Volunteers

Overall Official
Last Name Role Affiliation
Mohsen Bazargan, PhD Principal Investigator Charles R. Drew University of Medicine & Science
Overall Contact

Last Name: Mohsen Bazargan, PhD

Phone: 3233573655

Email: [email protected]

Location
Facility: Charles R. Drew University of Medicine & Science
Location Countries

United States

Verification Date

February 2021

Responsible Party

Type: Sponsor

Keywords
Has Expanded Access No
Condition Browse
Number Of Arms 3
Arm Group

Label: Arm 1

Type: Experimental

Description: This arm will include 5 churches who will receive all study activities in the Vaccine Education Promotion Management Plan

Label: Arm 2

Type: Experimental

Description: This arm will include 5 churches who will receive some study activities in the Vaccine Education Promotion Management Plan

Label: Arm 3

Type: Experimental

Description: This arm will include 5 churches who will receive all study activities in the Vaccine Education Promotion Management Plan following completion of Arm 1 and 2.

Patient Data No
Study Design Info

Allocation: Randomized

Intervention Model: Parallel Assignment

Intervention Model Description: The VEPMP will consist of recruited churches in 15 cohorts of 2 churches per cohort (total n = 30). Each cohort of church will include an AA and a Latinx church. The 15 church cohorts will be randomized to three arms based on a 1:1:1 ratio, using an online random number generator.

Primary Purpose: Health Services Research

Masking: None (Open Label)

Source: ClinicalTrials.gov